The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Outcomes of surgical management for borderline (BR)/locally advanced (LA) pancreatic adenocarcinoma (PAC) after neoadjuvant FOLFIRINOX chemotherapy: Results of an AGEO/French multicenter study.
Daniel Pietrasz
No relevant relationships to disclose
Lysiane Marthey
No relevant relationships to disclose
Mathilde Wagner
No relevant relationships to disclose
Jean-Frédéric Blanc
No relevant relationships to disclose
Eric Terrebonne
No relevant relationships to disclose
Antonio Sa Cunha
No relevant relationships to disclose
Romain Coriat
Consultant or Advisory Role - Keocyt; Novartis; Roche
Isabelle Trouilloud
No relevant relationships to disclose
Nicolas Regenet
No relevant relationships to disclose
Pascal Artru
Consultant or Advisory Role - Amgen; Merck Serono; Roche; Sanofi
Honoraria - Amgen; Merck Serono; Roche; Sanofi
Eric Francois
No relevant relationships to disclose
Lilian Schwarz
No relevant relationships to disclose
David Malka
No relevant relationships to disclose
Jean-Christophe Vaillant
No relevant relationships to disclose
Jean Baptiste Bachet
Consultant or Advisory Role - Amgen; Celgene; Roche; Sanofi
Honoraria - Bayer; Lilly; Merck Serono; Novartis
Mehdi Karoui
No relevant relationships to disclose